<DOC>
	<DOCNO>NCT00247390</DOCNO>
	<brief_summary>The purpose study determine long-term efficacy safety ramelteon , daily ( QD ) .</brief_summary>
	<brief_title>Long-Term Efficacy Safety Ramelteon Adults With Chronic Insomnia .</brief_title>
	<detailed_description>A vast majority people affect chronic insomnia western world . Several study look estimate 30 % 48 % general population affect time life form insomnia go several month , one third describe severely affected . Daytime symptoms insomnia include tiredness , lack energy , difficulty concentrating , irritability . Recent epidemiologic research focus quality life identify significant insomnia-related condition relate work productivity , health care utilization , risk depression . Insomnia associate diminished work output , absenteeism , great rate accident . An ideal treatment chronic insomnia would include administration therapy extend period . Specifically , safe effective period longer 7 10 day use current drug approve short-term use limit . Because absence evidence residual effect pre-clinical study phase 2 3 clinical trial , ramelteon may candidate extend use . As chronic insomnia become prevalent , need assess long-term efficacy safety nightly dose ramelteon general population . Study participation anticipate 8 month 3 week .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Body mass index 18 34 , inclusive . Based sleep history , chronic insomnia least 3 month . Based sleep history , report subjective sleep latency great equal 45 min subjective total sleep time le equal 6.5 hour . Based sleep history , habitual bedtime 10:00 PM 1:00 AM . Mean latency persistent sleep great 20 minute two consecutive screen night neither night le 15 minute . Also , mean 60 minute wake time 480 minute bed across two night night le 45 minute . Based sleep history , normally use pharmacological assistance sleep 0 4 time per week last 3 month . Exclusion Criteria Known hypersensitivity ramelteon related compound , include melatonin , melatonin related compound . Participated investigational study and/or take investigational drug within 30 day five halflives prior first dose singleblind study medication , whichever longer . Sleep schedule change require employment ( eg , shift worker ) within three month prior administration singleblind study medication . Flown across great three time zone within 7 day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior administration singleblind study medication . Has ever history seizure , sleep apnea , restless leg syndrome , periodic leg movement syndrome , chronic obstructive pulmonary disease fibromyalgia . History psychiatric disorder within past 6 month . History alcohol abuse within past 12 month , define Diagnostic &amp; Statistical Manual Mental Disorders , 4th Edition Revised , regularly consume 14 alcoholic drink per week , consume alcoholic drink within 24 hour polysomnogram visit . History drug abuse within past 12 month , define Diagnostic &amp; Statistical Manual Mental Disorders , 4th Edition Revised . Current significant hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic , neurological , metabolic disease , unless currently control stable protocolallowed medication , within 30 day prior first night singleblind study medication . Apnea hypopnea index ( per hour sleep ) great 10 see first polysomnogram screening night . Periodic Leg Movement Syndrome arousal index ( per hour sleep ) great 10 see first polysomnogram screening night . Positive urine drug screen Screening Visit 1 polysomnogram assessment visit . Positive breathalyzer test polysomnogram assessment visit . Uses tobacco product ( include nicotine gum patch ) product may interfere sleep wake cycle nightly awakening . Used central nervous system medication drug supplement know affect sleep/wake function within 1 week ( 5 half life drug , whichever long ) prior administration singleblind study medication . These medication must use treat psychiatric disorder . Intends continue take disallow medication prescription medication counter medication know affect sleep/wake function otherwise interfere evaluation study medication . The subject must report prescription counter medication take three week prior screen . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Anxiolytics Sedatives Hypnotics CNS active drug ( include herbal ) Antidepressants Narcotic analgesic Anticonvulsants Beta blocker Sedating H1 antihistamine St. John 's Wort Systemic steroid Kavakava Respiratory stimulant Ginkgobiloba Decongestants Overthecounter prescription stimulant Antipsychotics Overthecounter prescription diet aid Muscle Relaxants Melatonin drug supplement know affect sleep/wake function Any additional condition ( ) Investigator 's opinion would affect sleep/wake function prohibit subject complete study indicate continuation study would best interest subject . History hepatitis B hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>Sleep Initiation Maintenance Disorder</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>